RIPTACs represent a next-generation therapeutic strategy that selectively targets cancer cells through functional sequestration, offering a powerful alternative to traditional degradation-based approaches. This whitepaper showcases how BioDuro’s integrated in vitro platform utilizes Halda Therapeutics’ RIPTAC molecule to systematically validate mechanism, potency, and tumor selectivity—enabling accelerated development of precision oncology therapeutics.

• Core Mechanism Validation – Direct detection of ternary complex formation
• Tumor-Selective Cytotoxicity Profiling – Assessment across relevant cancer cell lines
• Functional Inhibition Confirmation – Downstream evaluation of target engagement
• Comprehensive Binding & Selectivity Analysis – Support for ligand optimization and safety

Download the full whitepaper to explore how our platform can advance your RIPTAC programs toward clinical success.